Teoxane, which holds a 6.2% stake in Revance and is a key customer of the Nashville, Tenn., company, had proposed buying the rest of the company for $3.60 a share after Crown reduced its planned ...

Maze Therapeutics, Inc MAZE IPO will take place January, 31 on the NASDAQ exchange under the ticker MAZE. The company is offering shares at an expected price between $15.00 and $17.00 per share with ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

Biotech company Metsera, which develops weight-loss drugs and is backed by ARCH Venture Partners, said on Monday that it is ...

Here's what's new in Bay Area biz news to start your workweek: tech stocks on wild ride, empty S.F. office buildings, copper ...

Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Maze Therapeutics is eyeing a $113 million initial public offering a little under two months after revealing a $115 million ...